GRAIL Overview
- Founded
- 2015
- Status
- Acquired/Merged
- Employees
- 700
- Latest Deal Type
- M&A
- Latest Deal Amount
- $7.1B
GRAIL General Information
Description
Operator a life sciences company created to detect cancer early when it can be cured. The company's the power of high-intensity sequencing, population-scale clinical trials, and state of the art Computer Science and Data Science to enhance the scientific understanding of cancer biology and develop blood tests for early-stage cancer detection, enabling doctors to get products for the early detection of cancer.
Contact Information
Website
www.grail.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Office
- 1525 O'Brien Drive
- Menlo Park, CA 94025
- United States
+1 (833) 000-0000
GRAIL Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 18-Aug-2021 | $7.1B | 000 | 00.00 | Completed | Generating Revenue |
| 5. IPO | 17-Mar-2021 | 00000 | Cancelled | Generating Revenue | ||
| 4. Later Stage VC (Series D) | 06-May-2020 | 00000 | 000 | 00.000 | Completed | Generating Revenue |
| 3. Later Stage VC (Series C) | 21-May-2018 | 00000 | 00.000 | 00.00 | Completed | Generating Revenue |
| 2. Later Stage VC (Series B) | 22-Nov-2017 | $1.21B | $1.31B | 00.000 | Completed | Generating Revenue |
| 1. Later Stage VC (Series A) | 08-Jan-2016 | $100M | $100M | 00000 | Completed | Startup |
GRAIL Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Series C | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.00 | |
| Series B | 309,256,591 | $0.001000 | $4.01 | $4.01 | 1x | $4.01 | 41.14% | |
| Series A | 85,000,000 | $0.001000 | $1 | $1 | 1x | $1 | 11.31% |
GRAIL Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator a life sciences company created to detect cancer early when it can be cured. The company's the power of high-in
Biotechnology
Menlo Park, CA
700
As of 2021
000
0.00
0000-00-00
000000&0
000
00000 00
esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in
0000000000 000000000
Madison, WI
0000
As of 0000
00.000
00000000
00.000
00000000
labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris ni
0000000000 000000000
Seattle, WA
00
As of 0000
0000
000
0000-00-00
00000000000
0000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialGRAIL Competitors (33)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Exact Sciences | Formerly VC-backed | Madison, WI | 0000 | 00.000 | 00000000 | 00.000 |
| 00000000 | Venture Capital-Backed | Seattle, WA | 00 | 0000 | 00000000000 | 0000 |
| 0000000 0000000000 | Venture Capital-Backed | Beverly, MA | 00 | 000.00 | 000000 0 | 000.00 |
| 0000000000 0000000 | Formerly VC-backed | Cambridge, MA | 0000 | 00000 | 00000000000 | |
| 000000000 | Venture Capital-Backed | Siena, Italy | 00 | 0000000000 0 |
GRAIL Patents
GRAIL Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210324477-A1 | Generating cancer detection panels according to a performance metric | Pending | 21-Apr-2020 | 000000000 | |
| US-20210313006-A1 | Cancer classification with genomic region modeling | Pending | 31-Mar-2020 | 0000000000 | |
| US-20210310075-A1 | Cancer classification with synthetic training samples | Pending | 30-Mar-2020 | 0000000000 | |
| US-20210285042-A1 | Systems and methods for calling variants using methylation sequencing data | Pending | 28-Feb-2020 | 000000000 | |
| US-20210292845-A1 | Identifying methylation patterns that discriminate or indicate a cancer condition | Pending | 28-Feb-2020 | C12Q1/6886 |
GRAIL Executive Team (14)
GRAIL Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Brook Byers Ph.D | Self | Board Member | 000 0000 |
| Catherine Friedman | Self | Chairman | 000 0000 |
| Hal Barron MD | Self | Board Member | 000 0000 |
| Kaye Foster | GRAIL | Board Member | 000 0000 |
| Maykin Ho Ph.D | Self | Board Member | 000 0000 |
GRAIL Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialGRAIL Former Investors (38)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| 6 Dimensions Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| ARCH Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Ally Bridge Group | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Amazon.com | Corporation | Minority | 000 0000 | 000000 0 | |
| Amino Capital | Venture Capital | Minority | 000 0000 | 000000 0 |
GRAIL Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 | 31-May-2017 | 0000000000 | Biotechnology | 0000000 0 |